Reporters from the country today, the thirteenth meeting of Clinical Oncology meeting was informed that, with completely independent
intellectual property rights of small molecule drugs targeting anti-cancer Innovation - Exeter erlotinib hydrochloride III clinical trial
results of published comparative studies
Studies show that its efficacy is not inferior to the international patent branded drug - gefitinib, safety has obvious advantages. This
indicates that small molecule anticancer drugs targeting the days of complete dependence on imports will become history.
Exeter erlotinib hydrochloride project has won the State Science and Technology's Innovation Fund, "863 Program", a major new drug projects,
the drug is the epidermal growth factor receptor kinase as target a new generation of targeted anti-cancer drug, is China Branch
Cancer experts in science workers and the first small independent original molecular targeted anti-cancer drug, was its first indication of
advanced non-small cell lung cancer.
It hosted the III clinical trials of the Chinese Academy of Engineering, Chinese Academy of Medical Sciences Cancer Hospital, Professor Sun
Yan introduced several of the new medicines are returned to America, Dr., after 8 years out of concentrated study.
National Cancer Hospital in 27 well-known III clinical trials research, to import drugs directly to gefitinib as a control drug, researchers
observed patients with advanced lung cancer after failure of chemotherapy efficacy and safety. This study is the first to create a
Large-scale clinical trials of anticancer drugs imported patented drugs for the control of the precedent.